MedTrace Logo

F 18 T807 Tau PET Imaging of Alzheimer's Disease

NCT02414347 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2024-07-17

No results posted yet for this study

Summary

A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.

Conditions

  • Alzheimer Disease

Interventions

DRUG

F 18 T807

Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.

Sponsors & Collaborators

  • Tammie L. S. Benzinger, MD, PhD

    lead OTHER

Principal Investigators

  • Tammie Benzinger, MD, PhD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-23
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414347 on ClinicalTrials.gov